P55 Real-world clinical and patient-reported outcomes of talimogene laherparepvec (T-VEC) treatment for melanoma in transit and nodal metastases at a UK centre

Abstract Talimogene laherparepvec (T-VEC) is a National Institute for Health and Care Excellence-approved oncolytic viral intralesional immunotherapy licensed unresectable stage III(B)–IV(M1a) melanoma. It genetically modified herpes simplex virus that selectively replicates in tumour cells, leading to local systemic antitumour immune responses, improving overall survival. The randomized phase III OPTiM trial reported complete response 28.2% of patients (Andtbacka RH, Collichio F, Harrington KJ et al. Final analyses OPTiM: talimogene vs. granulocyte-macrophage colony-stimulating factor III–IV J Immunother Cancer 2019; 7:145). We report retrospective review clinical patient-reported outcomes dermatology-led T-VEC service at regional UK melanoma centre between January 2019 2023. Treatment involves loading dose then two-weekly nurse-delivered injections. Patient demographics, characteristics, toxicities, treatment responses patient satisfaction were recorded. Sixteen (11 women five men) treated; the average age was 73 years (range 42–87). Seven had IIIB disease, six IIIC three IVM1a. Eight received prior nonsurgical treatments (adjuvant therapy, electrochemotherapy, diphencyprone). number lesions treated per visit ranged from 1 24 (median 5) over median visits 2–24). Four (25%) (CR), with time CR being 8 weeks; all have maintained 6–45 months). (50%) showed partial (PR), continuing treatment. Nine progressive disease (five PR group four who nonresponders). In total, died. Patients experienced mainly flu-like symptoms (44%), pyrexia (31%), fatigue (19%), muscle pain nausea headache diarrhoea (6%), joint swelling lymphadenopathy (6%) mild (25%). No grade 3 or 4 toxicity occurred. A questionnaire returned by seven eight completed All said they adequate information make decisions. Eighty-six cent rated excellent. Our results show comparable efficacy side-effects published trials demonstrate well-tolerated safe option, delaying potentially avoiding need more toxic agents. highlight dermatologists nurse specialists are well placed deliver